Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications

Yazar: Grossmann, Kenneth F., Margolin, Kim
Yayımlandı Ther Adv Med Oncol (2015)

The dark side of immunotherapy

Yazar: Okwundu, Nwanneka, Grossman, Douglas, Hu-Lieskovan, Siwen, Grossmann, Kenneth F., Swami, Umang
Yayımlandı Ann Transl Med (2021)

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)

Yazar: Anker, Christopher J., Grossmann, Kenneth F., Atkins, Michael B., Suneja, Gita, Tarhini, Ahmad A., Kirkwood, John M.
Yayımlandı Int J Radiat Oncol Biol Phys (2016)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab

Yazar: Moser, Justin C., Chen, Danli, Hu‐Lieskovan, Siwen, Grossmann, Kenneth F., Patel, Shiven, Colonna, Sarah V., Ying, Jian, Hyngstrom, John R.
Yayımlandı Cancer Med (2019)

Detection of Exosomal miRNAs in the Plasma of Melanoma Patients

Yazar: Pfeffer, Susan R., Grossmann, Kenneth F., Cassidy, Pamela B., Yang, Chuan He, Fan, Meiyun, Kopelovich, Levy, Leachman, Sancy A., Pfeffer, Lawrence M.
Yayımlandı J Clin Med (2015)

Clinical outcomes associated with evolving treatment modalities and radiation techniques for base-of-tongue carcinoma: thirty years of institutional experience

Yazar: Chen, Leechuan Andy, Anker, Christopher J, Hunt, Jason P, Buchmann, Luke O, Grossmann, Kenneth F, Boucher, Kenneth, Fang, Li-Ming Christine, Shrieve, Dennis C, Hitchcock, Ying J
Yayımlandı Cancer Med (2015)

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma

Yazar: Pokorny, Rebecca, McPherson, Jordan P, Haaland, Benjamin, Grossmann, Kenneth F, Luckett, Carolyn, Voorhies, Benjamin Newell, Sageser, Daniel S, Wallentine, Jocelyn, Tolman, Zachary, Hu-Lieskovan, Siwen, Swami, Umang
Yayımlandı J Immunother Cancer (2021)

Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours

Yazar: Nebot, Noelia, Arkenau, Hendrik‐Tobias, Infante, Jeffrey R., Chandler, Jason C., Weickhardt, Andrew, Lickliter, Jason D., Sarantopoulos, John, Gordon, Michael S., Mak, Gabriel, St‐Pierre, Annie, Tang, Lihua, Mookerjee, Bijoyesh, Carson, Stanley W., Hayes, Siobhan, Grossmann, Kenneth F.
Yayımlandı Br J Clin Pharmacol (2018)

The Small GTPase ARF6 Stimulates β-Catenin Transcriptional Activity During WNT5A-Mediated Melanoma Invasion and Metastasis

Yazar: Grossmann, Allie H., Yoo, Jae Hyuk, Clancy, James, Sorensen, Lise K., Sedgwick, Alanna, Tong, Zongzhong, Ostanin, Kirill, Rogers, Aaron, Grossmann, Kenneth F., Tripp, Sheryl R., Thomas, Kirk R., D’Souza-Schorey, Crislyn, Odelberg, Shannon J., Li, Dean Y.
Baskı/Yayın Bilgisi 2013

DNA Demethylase Activity Maintains Intestinal Cells in an Undifferentiated State Following Loss of APC

Yazar: Rai, Kunal, Sarkar, Sharmistha, Broadbent, Talmage J., Voas, Matthew, Grossmann, Kenneth F., Nadauld, Lincoln D., Dehghanizadeh, Somaye, Hagos, Fanuel T., Li, Yumei, Toth, Rachel K., Chidester, Stephanie, Bahr, Timothy M., Johnson, W. Evan, Sklow, Brad, Burt, Randall, Cairns, Bradley R., Jones, David A.
Baskı/Yayın Bilgisi 2010

A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma

Yazar: Ray, Abhijit, Williams, Matthew A., Meek, Stephanie M., Bowen, Randy C., Grossmann, Kenneth F., Andtbacka, Robert H.I., Bowles, Tawnya L., Hyngstrom, John R., Leachman, Sancy A., Grossman, Douglas, Bowen, Glen M., Holmen, Sheri L., VanBrocklin, Matthew W., Suneja, Gita, Khong, Hung T.
Yayımlandı Oncotarget (2016)

A Phase 2 Study of Dalantercept, an Activin Receptor-Like Kinase-1 Ligand Trap, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Yazar: Jimeno, Antonio, Posner, Marshall R., Wirth, Lori J., Saba, Nabil F., Cohen, Roger B., Popa, Elizabeta C., Argiris, Athanassios, Grossmann, Kenneth F., Sukari, Ammar, Wilson, Dawn, Zhang, Xiaosha, Sun, Jade, Glasser, Chad, Attie, Kenneth M., Sherman, Matthew L., Pandya, Susan S., Weiss, Jared
Yayımlandı Cancer (2016)

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF mutated melanoma: a randomized phase 2 trial

Yazar: Algazi, Alain P., Othus, Megan, Daud, Adil I., Lo, Roger S., Mehnert, Janice M., Truong, Thach-Giao, Conry, Robert, Kendra, Kari, Doolittle, Gary C., Clark, Joseph I., Messino, Michael J., Moore, Dennis F., Lao, Christopher, Faller, Bryan A., Govindarajan, Rangaswamy, Harker-Murray, Amy, Dreisbach, Luke, Moon, James, Grossmann, Kenneth F., Ribas, Antoni
Yayımlandı Nat Med (2020)

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

Yazar: Zakharia, Yousef, McWilliams, Robert R, Rixe, Olivier, Drabick, Joseph, Shaheen, Montaser F, Grossmann, Kenneth F, Kolhe, Ravindra, Pacholczyk, Rafal, Sadek, Ramses, Tennant, Lucinda L, Smith, Christopher M, Kennedy, Eugene P, Link Jr, Charles J, Vahanian, Nicholas N, Yu, Jiayi, Shen, Steven S, Brincks, Erik L, Rossi, Gabriela R, Munn, David, Milhem, Mohammed
Yayımlandı J Immunother Cancer (2021)

Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma

Yazar: Hodi, F Stephen, Chesney, Jason, Pavlick, Anna C, Robert, Caroline, Grossmann, Kenneth F., McDermott, David F, Linette, Gerald P, Meyer, Nicolas, Giguere, Jeffrey K, Agarwala, Sanjiv S, Shaheen, Montaser, Ernstoff, Marc S, Minor, David R, Salama, April K, Taylor, Matthew H, Ott, Patrick A, Horak, Christine, Gagnier, Paul, Jiang, Joel, Wolchok, Jedd D, Postow, Michael A
Yayımlandı Lancet Oncol (2016)

Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit

Yazar: Grossman, Douglas, Okwundu, Nwanneka, Bartlett, Edmund K., Marchetti, Michael A., Othus, Megan, Coit, Daniel G., Hartman, Rebecca I., Leachman, Sancy A., Berry, Elizabeth G., Korde, Larissa, Lee, Sandra J., Bar-Eli, Menashe, Berwick, Marianne, Bowles, Tawnya, Buchbinder, Elizabeth I., Burton, Elizabeth M., Chu, Emily Y., Curiel-Lewandrowski, Clara, Curtis, Julia A., Daud, Adil, Deacon, Dekker C., Ferris, Laura K., Gershenwald, Jeffrey E., Grossmann, Kenneth F., Hu-Lieskovan, Siwen, Hyngstrom, John, Jeter, Joanne M., Judson-Torres, Robert L., Kendra, Kari L., Kim, Caroline C., Kirkwood, John M., Lawson, David H., Leming, Philip D., Long, Georgina V., Marghoob, Ashfaq A., Mehnert, Janice M., Ming, Michael E., Nelson, Kelly C., Polsky, David, Scolyer, Richard A., Smith, Eric A., Sondak, Vernon K., Stark, Mitchell S., Stein, Jennifer A., Thompson, John A., Thompson, John F., Venna, Suraj S., Wei, Maria L., Swetter, Susan M.
Yayımlandı JAMA Dermatol (2020)

Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy

Yazar: Johnson, Mariah M, Leachman, Sancy A, Aspinwall, Lisa G, Cranmer, Lee D, Curiel-Lewandrowski, Clara, Sondak, Vernon K, Stemwedel, Clara E, Swetter, Susan M, Vetto, John, Bowles, Tawnya, Dellavalle, Robert P, Geskin, Larisa J, Grossman, Douglas, Grossmann, Kenneth F, Hawkes, Jason E, Jeter, Joanne M, Kim, Caroline C, Kirkwood, John M, Mangold, Aaron R, Meyskens, Frank, Ming, Michael E, Nelson, Kelly C, Piepkorn, Michael, Pollack, Brian P, Robinson, June K, Sober, Arthur J, Trotter, Shannon, Venna, Suraj S, Agarwala, Sanjiv, Alani, Rhoda, Averbook, Bruce, Bar, Anna, Becevic, Mirna, Box, Neil, E Carson, William, Cassidy, Pamela B, Chen, Suephy C, Chu, Emily Y, Ellis, Darrel L, Ferris, Laura K, Fisher, David E, Kendra, Kari, Lawson, David H, Leming, Philip D, Margolin, Kim A, Markovic, Svetomir, Martini, Mary C, Miller, Debbie, Sahni, Debjani, Sharfman, William H, Stein, Jennifer, Stratigos, Alexander J, Tarhini, Ahmad, Taylor, Matthew H, Wisco, Oliver J, Wong, Michael K
Yayımlandı Melanoma Manag (2017)